Prostate adenocarcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A carcinoma that arises from glandular epithelial cells of the prostate gland
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Prostate adenocarcinoma
- Therapeutic area
- Oncology
- prostate adenocarcinoma
- adenocarcinoma of prostate
- adenocarcinoma of the prostate
- prostate adenocarcinoma
- prostate gland adenocarcinoma
- prad
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0005082
- Parent condition
- MONDO:0004970
Related records
Broader conditions (22)
- Adenocarcinoma
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Epithelial neoplasm
- Glandular cell neoplasm
- Human disease
- Male reproductive organ cancer
- Male reproductive system disorder
- Male reproductive system neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Prostate cancer
- Prostate carcinoma
- Prostate disorder
- Prostate neoplasm
- Reproductive system cancer
Narrower conditions (6)
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Lymphoepithelioma-like acinar prostate adenocarcinoma
- Prostate adenoid cystic carcinoma
- Prostatic acinar adenocarcinoma
Trials (429)
- 131-I-TM-601 Study in Adults With Solid Tumors
- 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
- 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study
- 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
- 68Ga-PSMA-11 PET in Patients With Prostate Cancer
- 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
- 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
- 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
- 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
- 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
- A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer
- A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
- A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
- A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer
- A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
- A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
- A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
Approved drugs (21)
- Abiraterone acetate
- Apalutamide
- Cabazitaxel
- Choline C-11
- Darolutamide
- Degarelix acetate
- Docetaxel
- Dutasteride
- Enzalutamide
- Finasteride
- Fluciclovine F18
- Flutamide
- Histrelin acetate
- Leuprolide acetate
- Mitoxantrone hydrochloride
- Nilutamide
- Piflufolastat F18
- Radium RA 223 dichloride
- Relugolix
- Triptorelin pamoate
Drugs in development (215)
- Abemaciclib Phase 1
- Abiraterone Phase 3
- Adakitug Phase 1
- Afatinib Phase 2
- Alendronic acid Phase 3
- Alisertib Phase 2
- Amifostine Phase 2
- Antineoplaston A10 Phase 2
- Arundine Phase 1
- Ascorbic acid Phase 2
- Aspirin Phase 2
- Atezolizumab Phase 3
- Atorvastatin Phase 3
- Atrasentan Phase 3
- Axitinib Phase 2
- Azacitidine Phase 2
- Bavituximab Phase 1
- Bevacizumab Phase 3
- BI-2536 Phase 2
- Bicalutamide Phase 3